GLP-1 Receptor Agonist — Ozempic / Wegovy / Rybelsus
A synthetic analogue of glucagon-like peptide-1 (GLP-1) that has fundamentally reshaped metabolic medicine. FDA-approved for type 2 diabetes and obesity, semaglutide produces weight loss of 15–20% in clinical trials — the most powerful pharmacological weight loss effect ever documented. Now the most prescribed and searched peptide-class compound in history.
01 — Research Summary
Semaglutide has one of the most robust clinical evidence bases of any compound in this space — backed by major Phase 3 trials involving tens of thousands of participants. The SUSTAIN, STEP, and SELECT trial programmes have collectively produced landmark findings across weight loss, cardiovascular risk, and metabolic disease.
20% reduction in major cardiovascular events. The SELECT trial demonstrated that semaglutide significantly reduced the risk of heart attack, stroke, and cardiovascular death in overweight or obese adults without diabetes — establishing cardiovascular protection independent of weight loss effects.
14.9% average body weight reduction. The landmark STEP 1 trial showed weekly subcutaneous semaglutide 2.4mg produced nearly 15% weight loss over 68 weeks — roughly double the efficacy of previous generation obesity medications. A third of participants lost more than 20%.
Kidney protection in diabetic nephropathy. FLOW trial data showed semaglutide significantly slowed progression of kidney disease in patients with type 2 diabetes and chronic kidney disease — expanding the therapeutic profile beyond glycaemic control and weight.
Emerging evidence in addiction and neurodegeneration. Observational studies and mechanistic research suggest GLP-1 receptor agonism reduces addictive behaviour (alcohol, nicotine, opioids) and may be neuroprotective. Multiple clinical trials in Alzheimer's and Parkinson's are underway as of 2024.
Superior HbA1c reduction vs. all comparators. Across the SUSTAIN programme, semaglutide consistently outperformed insulin glargine, sitagliptin, exenatide, and dulaglutide for HbA1c reduction — establishing it as the most effective GLP-1 agonist for glycaemic control at the time.
02 — Mechanism of Action
Semaglutide mimics native GLP-1, a hormone released from the gut after eating, but with a 7-day half-life versus minutes for endogenous GLP-1. This sustained receptor engagement drives effects across the pancreas, brain, gut, and cardiovascular system simultaneously.
Semaglutide binds GLP-1 receptors expressed across multiple organ systems. The fatty acid chain modification allows albumin binding in the bloodstream, extending half-life from minutes (native GLP-1) to approximately 7 days — enabling once-weekly dosing.
In the pancreas, semaglutide stimulates glucose-dependent insulin secretion and suppresses glucagon release. The glucose-dependence is critical for safety — insulin is only released when blood glucose is elevated, significantly reducing hypoglycaemia risk.
GLP-1 receptors in the hypothalamus and brainstem mediate semaglutide's most commercially significant effect — powerful appetite reduction. The compound reduces food intake, increases satiety signals, and reduces the hedonic drive to eat. Patients consistently report food "noise" dramatically quietening.
Semaglutide slows gastric emptying, extending the duration of post-meal satiety. This contributes to reduced caloric intake and flatter post-meal glucose spikes. It also accounts for the nausea experienced by many users, particularly during dose escalation.
Direct GLP-1 receptor activity in the heart and vasculature drives anti-inflammatory, anti-atherosclerotic, and cardioprotective effects. These effects appear partly independent of weight loss, as the SELECT trial enrolled non-diabetic participants and still showed significant cardiovascular risk reduction.
Unlike most weight loss interventions, semaglutide appears to preserve lean muscle mass while reducing fat mass — though this is dose and protocol dependent. Combining with resistance training and adequate protein intake is strongly recommended to maximise body composition outcomes.
03 — Dosing Protocols
Semaglutide uses a mandatory dose escalation schedule to minimise GI side effects. Jumping to the therapeutic dose immediately produces significantly higher rates of nausea and discontinuation.
| Phase | Dose | Duration | Purpose |
|---|---|---|---|
| Escalation Phase 1 | 0.25 mg/week | 4 weeks | Tolerance building. Not a therapeutic dose — GI adaptation only. |
| Escalation Phase 2 | 0.5 mg/week | 4 weeks | Continued adaptation. Some glycaemic benefit begins here. |
| Maintenance (T2D) | 1.0 mg/week | Ongoing | Standard therapeutic dose for type 2 diabetes management. |
| Maintenance (obesity) | 2.4 mg/week | Ongoing | Wegovy dose used in STEP trials. Maximum weight loss benefit. |
| Compounded / research | 0.5–2.4 mg/week | Varies | Research-grade compounded semaglutide — significant quality variance. |
The FDA has raised concerns about compounded semaglutide quality, including incorrect dosing, contamination, and use of salt forms (semaglutide sodium/acetate) not studied in clinical trials. If using compounded product, source verification is critical. Branded Ozempic/Wegovy carry a significant cost premium but known quality.
04 — Community Experiences
Semaglutide has the largest community evidence base of any compound on this site — driven by mainstream adoption and millions of users globally. The conversation spans from clinical patients on branded Ozempic/Wegovy through to biohackers using compounded versions. Key themes: the "food noise" silencing effect is consistently cited as transformative; GI side effects during escalation are common but usually manageable; and muscle loss concerns have driven a strong secondary discussion around protein intake and resistance training on GLP-1s.
These are user-reported experiences from public forums. Individual results vary significantly. Semaglutide is FDA-approved and should ideally be used under medical supervision.
"I didn't realise other people didn't have a constant internal monologue about food until I went on semaglutide and it just... stopped. I've been overweight my entire adult life and I never knew this is what thin people experience every day..."
"Weeks 2–4 were rough. Small meals, slow eating, ginger tea, and staying strictly on the escalation schedule made it manageable. Weeks 6 onwards and I barely notice any GI issues now. Don't quit during the escalation phase..."
"The DEXA data is clear — you will lose muscle on semaglutide if you don't actively fight it. 1.6g protein per kg bodyweight minimum, resistance training 3x per week, and consider adding a preservation peptide. This is not optional..."
"Lost 22kg. Cost me a fraction of branded Ozempic. The quality does vary significantly between compounding pharmacies — I did a lot of research on this. Results took a bit longer to kick in vs. people on branded, but ultimately worked..."